Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Circulating Tumor Cells in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Histologically or cytologically confirmed breast cancer~* Metastatic breast cancer (stage IIIB and IV). EGFR and/or HER-2 expression on the primary tumor is not mandatory.~* Patients should have received at least one course of standard systemic chemotherapy for their metastatic disease. Prior hormonal therapy is allowed.~* Patients should have achieved objective response (CR or PR) or stable disease to previous first or second line treatment.~* There should be at least one month between the end of chemotherapy treatment and trial entry. In case of prior Herceptin administration, 3 months are required to have elapsed before study entry.~* Detection of ≥5 cells/7.5ml of peripheral blood detected by Cell Search System despite the previous administration of chemotherapy and/or hormonal therapy.~* HER-2 expression on CTCs.~* Age 18 years and over~* Adequate Haematological function, Absolute neutrophil count ≥1.5 x 109/L, Platelet count ≥100 x 109/L and Haemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level)~* Adequate Liver Function, total bilirubin \<1.5 x upper limit of normal, AST and ALT \<2.5 x upper limit of normal in patients without liver metastases and \<5 x upper limit of normal in patients with liver metastases~* Adequate Renal function, Serum creatinine ≤1.25 x upper limit of normal or calculated creatinine clearance ≥50 mL/min~* LVEF within institutional normal range~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Any concurrent systemic treatment for breast cancer (including chemotherapy, radiotherapy, hormonotherapy, monoclonal antibodies)~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ~* Any unresolved chronic toxicity greater than Grade 2 (NCI- CTCAE) from previous anticancer therapy (except alopecia)~* Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)~* Pregnancy or breast feeding (women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy~* Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment~* Known hypersensitivity to drugs chemically related to lapatinib~* Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors~* Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lapatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete